There were 422 press releases posted in the last 24 hours and 158,742 in the last 365 days.

Vitamin Deficiency & Balding: Lilac Corp reviews a study, & recommends Nolopecia, a natural treatment against hair loss

All natural hair loss supplement sold by Lilac Corp

Low levels of certain vitamins may be related to hair loss

Nolopecia is a natural treatment against hair loss that works by targeting latent viruses.

For men and women, who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. The new treatment targets the latent viruses in the body.”
— Lilac Corp
SARASOTA, FL, UNITED STATES, June 12, 2018 / -- Hair loss is a distressing and common condition that affects up to 50 percent of men and women throughout their lives [1]. A study [2] found low levels of vitamin D, vitamin B-12, and iron in a significant number of women suffering from hair loss. More specifically, blood tests on 100 women with signs of hair loss showed that 81% of them had low levels of vitamin D, 76% of them had low vitamin B-12, and 57% had low levels of iron. Incidentally, 11% of the women were discovered to also have a thyroid disorder. The study concluded that nutritional support and vitamin supplementation may be helpful in the treatment of hair loss in women. The study also suggested that women suffering from hair loss should have their thyroid tested.

For men and women, who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. The new treatment targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth. There are many treatments for hair loss on the market. However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin. For more information on these products, see, or search Google. The search will produce the clinical studies that tested the treatments and showed the safety and effectiveness of the treatments. See also references below.

About Lilac Corp:
Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world. What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

[1] Price VH. Treatment of hair loss. N Engl J Med. 1999;341(13):964–973

[2] Poonia, K., Thami, G., Bhalla, M., Jaiswal, S., & Sandhu, J. (2018). NonScarring Diffuse Hair Loss in Women: a Clinico-Etiological Study from tertiary care center in North-West India. Journal Of Cosmetic Dermatology. doi: 10.1111/jocd.12559

[3] Polansky H, Javaherian A, Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir. Drug Des Devel Ther. 2016 Aug 29;10:2713-22

[4] Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.

[5] Polansky H, Itzkovitz E, Javaherian A. Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus. Drug Des Devel Ther. 2017 Mar 3; 11:575-583

John Evans
Lilac Corp
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.